Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.39 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 2/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963222 | 0.82 | RNASE1 (0.46) | TK2RNASE1TK1 | |
| SCHEMBL20518491 | 0.79 | TK2 (0.41) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL23387397 | 0.78 | TK2 (0.41) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL23387096 | 0.76 | TK2 (0.40) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL13837083 | 0.76 | RNASE1 (0.39) | TK2RNASE1 | |
| SCHEMBL30396393 | 0.74 | — | — | |
| SCHEMBL29529114 | 0.73 | TK2 (0.40) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL30679319 | 0.73 | TK2 (0.40) | TK2RNASE1CA12CA5ACA7 | |
| SCHEMBL13837086 | 0.72 | TK2 (0.37) | TK2RNASE1 | |
| SCHEMBL29834210 | 0.71 | TK2 (0.42) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | NUDT1, RNGTT, POLN | TK2 92/4885RNASE1 251/4885CA12 3989/4885 |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | TK2 224/4885RNASE1 89/4885CA12 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.